Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Vascular Endothelial Growth Factor and Neuropathy

    Vascular Endothelial Growth Factor and Neuropathy

    February 1, 2011
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Anti-VEGF Therapies Induce Painful Sensory Neuropathy

    Independent Risk Factors for Diabetic Neuropathy

    Keywords

    Neurology

    Vascular Endothelial Growth Factor and Neuropathy

    Abstract & Commentary

    By Michael Rubin, MD, Professor of Clinical Neurology, Weill Cornell Medical College. Dr. Rubin reports no financial relationships relevant to this field of study.

    Synopsis: VEGF is elevated in the serum and plays a role in the pathogenesis of neuropathies associated with monoclonal gammopathies.

    Source: Briani C, Fabrizi GM, Ruggero S, et al. Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias. Muscle Nerve http://www.ncbi.nlm.nih.gov/pubmed/21082697

    Can measurement of serum vascular endothelial growth factor (sVEGF) aid in the diagnosis of neuropathy and predict disease course? sVEGF is increased in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes), less so in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (in spite of a similar demyelinating pathology), and is not significantly elevated in multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS). sVEGF levels in amyloidosis have not been systematically studied.

    To evaluate sVEGF levels in amyloidosis and its response to treatment, 25 patients (18 men and 7 women, mean age 66.8 years) with biopsy-proven amyloidosis were evaluated, including 17 (10 men and 7 women) with primary amyloidosis (AL-A), 7 men with transthyretin amyloidosis (TTR-A), and 1 man with senile systemic (wild-type TTR) amyloidosis. TTR-A was diagnosed by molecular analysis and confirmed with sural nerve biopsy. TTR-positive immuno-histochemistry confirmed the diagnosis of senile (wild-type TTR) amyloidosis, whereas primary AL-A was diagnosed by the presence of monoclonal light chain protein in urine or serum, abnormal serum free light chain ratio, or monoclonal plasma cells in bone marrow with negative immuno-histochemistry for TTR and absence of TTR mutation on DNA analysis. Seven TTR-A patients and 3 AL-A patients had an axonal sensory polyneuropathy, and 6 TTR-A patients had autonomic polyneuropathy. sVEGF levels were measured by ELISA (enzyme-linked immunosorbent assay). Statistical analysis included the Mann-Whitney U-test and the Kruskal-Wallis test, with significance set at P < 0.05.

    sVEGF levels were significantly lower in patients with AL-A (median 420 pg/ml) and TTR-A (median 179 pg/ml) compared to those with POEMS syndrome (median 2580 pg/ml). Multiple myeloma median sVEGF level, 260 pg/ml, was also significantly lower than seen in POEMS syndrome. Presence or absence of neuropathy in AL-A did not affect sVEGF level and it did not vary with disease status or therapeutic response. sVEGF measurement can assist in differentiating POEMS from CIDP, MGUS-neuropathy, and amyloidosis, and should be measured in patients with plasma cell dyscrasias and neuropathy.

    Commentary

    Angiogenesis and lymphangiogenesis, critical processes during embryogenesis, tissue growth, wound healing, and disease pathogenesis, are regulated via activation of three receptor tyrosine kinases, VEGFR-1, 2, and 3, by vascular endothelial growth factors (VEGFs). Vascular permeability and vessel dilatation are regulated by these receptors, and VEGF also has, both in vivo and in vitro, direct trophic effects on neuronal cells. Demyelinating neuropathy in POEMS may result from blood-nerve barrier dysfunction mediated by increased levels of circulating VEGF. Yet the mechanism for POEMS remains a puzzle. It is unclear why lambda light chain predominates in POEMS, as opposed to kappa light chain that predominates in MGUS, though both present similar demyelinating neuropathies. Vascular leakage is suggested by the presence of hepatomegaly and splenomegaly in POEMS, attributed to elevated circulating VEGF levels, but other factors, including interleukin-1β, interleukin-6, and tumor necrosis factor α, are also elevated in POEMS and may play a role in pathogenesis.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert 2011-02-01
    February 1, 2011

    Table Of Contents

    Vascular Endothelial Growth Factor and Neuropathy

    The ABCs of Anosognosia for Hemiplegia

    Sleep Disorders and Restless Legs Syndrome in Friedreich's Ataxia

    Gait Ataxia in Essential Tremor Modulated by Thalamic Deep Brain Stimulation

    A Hereditary, Childhood Form of Parkinsonism

    Stroke Alert: A Review of Current Clinical Stroke Literature

    Clinical Briefs in Primary Care Supplement

    Pharmacology Watch

    Begin Test
    Buy this Issue/Course

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events

    Free Email Newsletters

    All Fields Required

    E-Newsletter Options
    • Accreditation Council for Continuing Medical Education
    • American Nurses Credentialing Center
    • American College of Emergency Physician
    • American Board of Internal Medicine: Maintenance of Certification
    • California Board of Registered Nursing
    • Commission for Case Manager Certification
    • American Academy of Pediatrics
    • American Osteopathic Association
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2019 Relias. All rights reserved.

    Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing